Hemophagocytic Lymphohistiocytosis Secondary to Cytomegalovirus in a Kidney Transplant Recipient with DiGeorge Syndrome (ATC 2026) - Jun 17, 2026 - Abstract #Abstract B366; Pres time: Jun 21, 2026; 02:45 PM - 03:45 PM; Location: Exhibit Hall; "Induction immunosuppression included alemtuzumab, followed by maintenance therapy with Belatacept, mycophenolate mofetil (MMF), and prednisone. Tacrolimus was avoided due to seizure risk, and Everolimus was deferred because of wound-healing concerns...She was initially treated with intravenous Ganciclovir, later transitioned to oral Valganciclovir, and subsequently maintained on Letermovir for prophylaxis... This case illustrates the diagnostic and therapeutic challenges of HLH in immunocompromised transplant recipients with underlying immune deficiency. Profound T-cell depletion from alemtuzumab, superimposed on the congenital T-cell dysfunction of DiGeorge syndrome, likely predisposed to severe CMV reactivation and secondary HLH. Importantly, our patient achieved clinical resolution with targeted antiviral therapy and IVIG alone, without the need for cytotoxic or high-dose corticosteroid therapy."
Clinical • CNS Disorders • Cough • Cytomegalovirus Infection • Dyslipidemia • Epilepsy • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Hypertriglyceridemia • Immunology • Infectious Disease • Nephrology • Primary Immunodeficiency • Rare Diseases • Renal Disease • Respiratory Diseases • Solid Organ Transplantation • Transplantation • IL2 • IL2RA
|